Stock Price
144.35
Daily Change
0.25 0.17%
Monthly
16.43%
Yearly
19.65%
Q3 Forecast
142.90

Neurocrine Biosciences reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.




Loan Capital Change Date
AbbVie USD 64.53B 4.19B Mar/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 1.03B 956K Jun/2025
Amgen USD 53.76B 253M Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
BioMarin Pharmaceutical USD 596.16M 512K Jun/2025
Cytokinetics USD 713.04M 67.88M Jun/2025
Dynavax Technologies USD 220.75M 39.75M Jun/2025
Exelixis USD 0 0 Apr/2025
Gilead Sciences USD 22.14B 6M Jun/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Incyte USD 31.76M 883K Jun/2025
Ionis Pharmaceuticals USD 625.49M 625.22M Jun/2025
Neurocrine Biosciences USD 0 0 Dec/2024
Pfizer USD 57.5B 137M Jun/2025
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 1.99B 719.7M Jun/2025
Repligen USD 533.72M 4.12M Jun/2025
Sarepta Therapeutics USD 1.14B 1.17M Jun/2025
Teva Pharmaceutical Industries USD 16.76B 533M Jun/2025
Ultragenyx Pharmaceutical USD 782.75M 782.75M Jun/2025
Vertex Pharmaceuticals USD 112.8M 1.2M Dec/2024